Eric Shen is Chief of Staff at the T1D Fund, where he partners with the leadership team to translate strategy into operating plans and drive execution across fundraising, portfolio support, and internal operations. He leads day-to-day firm operations, governance implementation, and financial planning, coordinating across finance, legal, compliance, and external partners.

Prior to joining the Fund, Eric was the Director of Corporate Development & Operations at Kojin Therapeutics, where he led corporate development, investor relations, finance, and strategic planning in partnership with the C-suite. Earlier in his career, he held corporate development and operational roles at Pear Therapeutics and Ohana Biosciences (Flagship Pioneering), and helped grow Old Silver Venture Capital, a venture capital firm supporting early-stage investments across biotech and digital health.

Eric earned a B.A. in Biology with a minor in Business from Brandeis University.

Sylvia Tobé is a biotech industry professional with more than 10 years of experience across venture investing, company creation, and translational science. Prior to joining the T1D Fund, she was a Principal at Omega Funds, where she focused on early-stage investments and company formation across various therapeutic areas including neurology, immunology, and rare diseases. She currently serves on the Boards of DiogenX, ZagBio and Islex Therapeutics and has held Board observer roles at various biotech companies including Zucara Therapeutics, Vanqua Bio, Rectify Pharma and others.

Before Omega, Sylvia spent nearly seven years at Ra Pharmaceuticals, a peptide drug discovery company focused on complement-driven rare diseases. At Ra, she contributed to the development of the company’s discovery platform and helped build preclinical and translational models supporting first-in-human studies for its lead program, Zilucoplan, now approved in multiple countries for generalized myasthenia gravis (gMG). She also provided scientific leadership across multiple internal and partnered discovery programs, including a collaboration with Merk.

Sylvia earned her Ph.D. in Biochemistry (Summa Cum Laude) from Pierre and Marie Curie University in Paris while serving as a full-time visiting fellow in the Department of Genetics at Harvard University, where she worked in synthetic biology. She also holds an M.S. from Pierre and Marie Curie University and a B.S. in Biochemistry from Joseph Fourier University in Grenoble.